Ashfield and IPCAA join forces to find out what HCPs really think about virtual medical congresses in new global study.
Ashfield Meetings & Events (part of UDG Healthcare PLC) and the International Pharmaceutical Congress Advisory Association (IPCAA) today released a study which reveals what healthcare professionals really think about virtual medical congresses.
Through a survey of more than 300 physicians from six countries (US and EU) and across 14 therapy areas, the global healthcare meetings specialist and the advisory association have gained detailed insights that are set to help medical societies, professional congress organizers (PCOs), and the industry consider how to shape virtual congresses of the future.
The study – the second part of which is planned for before the end of 2020 – looks at a variety of elements of the virtual congress, highlighting HCPs’ thoughts on accessibility and technology, how they viewed the online activities including industry symposia and poster sessions, and connecting with industry and peers.
For a summary report of IPCAA and Ashfield’s initial findings, click here.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.